Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa Bay news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Charlotte news in your inbox

Catch up on the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A healthcare worker administers a coronavirus swab test on Dec. 6 in Mumbai, India. Photo: Satyabrata Tripathy/Hindustan Times via Getty Images

India is reviewing the COVID-19 vaccines developed by Pfizer and AstraZeneca for emergency use, Reuters reports.

Why it matters: India is home to the Serum Institute, the largest vaccine manufacturer in the world by volume. The country has also reported the most coronavirus cases outside the U.S., and the third-most COVID fatalities globally, per Johns Hopkins University data.

  • Daily coronavirus cases in India have gradually declined since September, but the country is still seeing several hundred deaths per day.

Driving the news: Serum Institute CEO Adar Poonawalla tweeted on Monday that the company had applied for an emergency use authorization of the AstraZeneca vaccine. Poonawalla also thanked Prime Minister Narendra Modi for his support.

  • Pfizer applied for authorization from the Drugs Controller General of India late last week, the Times of India reports

Context: AstraZeneca CEO Pascal Soriot said last month that the company is likely to start a new global trial to measure the efficacy of its COVID vaccine, after a smaller dose received by some participants in its last trial was found to be the result of an error by a contractor.

  • Top scientists at the World Health Organization have called for more detailed information on AstraZeneca's vaccine. The company says the vaccine is 90% effective in people who got a half dose followed by a full dose, and 62% effective in people who got two full doses.
  • The U.K. government approved Pfizer-BioNTech's vaccine last week, after the company said the vaccine is 95% effective and has no serious side effects.

Go deeper

Jan 26, 2021 - Health

U.K. surpasses 100,000 COVID-19 deaths

Photo: Owen Humphreys/PA Images via Getty Images

The U.K. on Tuesday surpassed 100,000 coronavirus deaths almost a year after the first two cases were reported in the country, according to government figures.

Why it matters: It is the first European country and fifth country in the world to reach the threshold. The country reported 100,162 deaths on Tuesday.

Scammers have stolen over $130 million in coronavirus-related schemes

Photo: Chip Somodevilla/Getty Images

Over 100,000 Americans have collectively reported roughly $132 million in fraud losses from scams related to the coronavirus and government stimulus checks since the March start of the pandemic, according to the Federal Trade Commission.

Why it matters: Coronavirus-related fraud complaints peaked in May when the IRS began sending its first round of stimulus checks. Congress recently proposed a second round of stimulus.